GLENMARK PHARMA Results Analysis-Q4FY26

$GLENMARK Operating Revenue for Q4FY26 is Rs. 3,771 Crs. 15.8% growth YoY, Total Income is Rs. 3,960 Crs., 21.17% growth YoY, Gross Profit is Rs. 2,598 Crs., 19.89% growth YoY, EBITDA is Rs. 763 Crs., 35.93% growth YoY, PBT Rs. 388 Crs. 4765.37% growth YoY, PAT Rs. 301 Crs. 6779% growth. On QoQ basis Op. Revenue is down by 3.3%, Total Income is flat to positive, Gross Profit is flat to negative, However EBITDA is down by 12.32%, PBT is down by 27.38% and PAT is also up by 25.27%. India business growth of 8.2%, North America core business growth of 7.8%, EU business growth of 21.4%, EM business growth of 13.7%. India business delivered strong outperformance in secondary sales, 1.5x the IPM growth, 2nd fastestgrowing company among the top 15 companies IGI secured a landmark licensing deal with AbbVie for ISB 2001, USD 700 million upfront payment with potential total deal value of USD 1.925 billion, tiered double digit royalties on net sales; Glenmark to commercialize in Emerging Markets.